Last kr7.80 DKK
Change Today 0.00 / 0.00%
Volume 43.1K
EXQ On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
As of 11:02 AM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

exiqon a/s (EXQ) Snapshot

Open
kr7.85
Previous Close
kr7.80
Day High
kr7.85
Day Low
kr7.60
52 Week High
02/6/14 - kr9.70
52 Week Low
07/25/14 - kr7.60
Market Cap
287.6M
Average Volume 10 Days
13.9K
EPS TTM
kr-0.15
Shares Outstanding
36.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXIQON A/S (EXQ)

Related News

No related news articles were found.

exiqon a/s (EXQ) Related Businessweek News

No Related Businessweek News Found

exiqon a/s (EXQ) Details

Exiqon A/S provides products for microRNA research worldwide. It operates through the Life Sciences and Diagnostics segments. The company’s products serve as a platform for the development of molecular diagnostic tests. It develops molecular diagnostic tests in collaboration with pharmaceutical and diagnostic companies. The company’s products include RNA isolation kits; microRNA Array system, a system for global microRNA expression profiling; microRNA qPCR system, which enables microRNA expression profiling; microRNA detection probes that are used for the ultra-sensitive and detection of microRNAs by Northern blot analysis and in situ hybridization; and microRNA inhibitor and target site blockers for functional analysis of microRNAs. It also offers microarrays capture probes for expression analysis of splice variants, small RNAs, and even mRNA; qPCR assays for mRNA and ncRNA; RNA detection probes for in situ hybridization and Northern blot; longRNA GapmeR, which are antisense oligonucleotides used for the inhibition of mRNA and lncRNA function; oligonucleotides to detect single nucleotide polymorphism (SNP); SNP microarrays; FISH probes to detect chromosomal DNA sequences; custom LNA oligonucleotides; LNA phosphoramidites for the synthesis of LNA containing oligonucleotides; and A2-quencher phosphoramidite, a dark quencher developed for real-time PCR probes. In addition, the company provides RNA isolation services for the sample types, including blood derived serum, plasma and other bio-fluids, clinical FFPE and fresh frozen tissues, and cell lines; MicroRNA array services; MicroRNA profiling services; microRNA and Small RNA sequencing services; microRNA in situ hybridization screening services; and custom pharma services. Exiqon A/S markets its research products through direct sales, distributors, and the Web. The company was founded in 1995 and is headquartered in Vedbaek, Denmark.

83 Employees
Last Reported Date: 05/6/14
Founded in 1995

exiqon a/s (EXQ) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

exiqon a/s (EXQ) Key Developments

Exiqon A/S Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for 2014

Exiqon A/S reported unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported revenue of DKK 32,471,000 against DKK 31,765,000 a year ago. EBITDA was DKK 1,646,000 against LBITDA of DKK 2,045,000 a year ago. Operating profit was DKK DKK 471,000 against operating loss of DKK 3,369,000 a year ago. Profit for the period was DKK 793,000 or DKK 0.02 per diluted share against loss for the period of DKK 4,470,000 or DKK 0.12 per diluted share a year ago. Cash flows used in operating activities were DKK 2,312,000 against DKK 3,189,000 a year ago. Acquisition of property, plant and equipment was DKK 480,000 against DKK 119,000 a year ago. In 2014. the company expects revenue of approximately DKK 150 million and EBITDA around DKK 5 million.

Exiqon A/S Approves to Update the Provisions in Articles of Association

Exiqon A/S at annual general meeting held on 25 March 2014, approved to update the provisions in the articles of association regarding warrants as proposed by the supervisory board.

Exiqon A/S Announces Group and Parent Earnings Results for the Fourth Quarter and Full Year of 2013; Provides Earnings Guidance for the Fiscal Year 2014

Exiqon A/S announced Group and parent earnings results for the fourth quarter and full year of 2013. For the quarter, on group basis, revenue was DKK 28.7 million against DKK 34.3 million a year ago. LBITDA was DKK 2.6 million against EBITD of DKK 1.7 million a year ago. Net loss was DKK 3.2 million against DKK 1.5 million a year ago. LPS was DKK 0.09 against DKK 0.04 a year ago. Cash flows from operating activities were DKK 4.3 million against DKK 4.8 million a year ago. LPS was DKK 0.09 against DKK 0.04 a year ago. For the year, on group basis, revenue was DKK 123,584,000 against DKK 117,400,000 a year ago. Operating loss(LBIT) was DKK 8,780,000 against DKK 11,777,000 a year ago. Loss before tax was DKK 11,508,000 against DKK 13,665,000 a year ago. Loss for the year was DKK 10,682,000 or DKK 0.29 per diluted share against DKK 14,595,000 or DKK 0.41 per diluted share a year ago. Cash flows from operating activities were DKK 3,228,000 against cash flow used in operating activities of DKK 5,411,000 a year ago. For the year, on parent basis, revenue was DKK 102,243,000 against DKK 97,071,000 a year ago. Operating loss(LBIT) was DKK 9,720,000 against DKK 13,120,000 a year ago. Loss before tax was DKK 12,436,000 against DKK 14,057,000 a year ago. Loss for the year was DKK 11,186,000 against DKK 12,807,000 a year ago. Cash flows from operating activities were DKK 3,095,000 against cash flow used in operating activities of DKK 3,464,000 a year ago. For the fiscal year 2014, the company expects revenue of approximately DKK 150 million and EBITDA around DKK 5 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EXQ:DC kr7.80 DKK 0.00

EXQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $8.36 USD -0.01
Fluidigm Corp $27.68 USD -0.66
Luminex Corp $17.61 USD +0.51
NanoString Technologies Inc $12.37 USD -0.10
QIAGEN NV €18.43 EUR +0.006
View Industry Companies
 

Industry Analysis

EXQ

Industry Average

Valuation EXQ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXIQON A/S, please visit www.exiqon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.